Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.

Abstract

We have previously shown that HIV p24-like peptides (Vacc-4x) via activation of skin dendritic cells induced immune responses in 90% of HIV patients on highly active antiretroviral treatment (HAART). These patients (n=38) were here subjected to a final 14-week interruption of HAART. Patients with the highest delayed type hypersensitivity (DTH) responses to Vacc-4x-peptides before treatment interruption tended to achieve lower actual HIV RNA levels at the end of the study compared to Vacc-4x DTH low-responders (p=0.08) and significantly so in terms of viral loads relative to their individual pre-HAART HIV RNA set-points (p=0.04). CD4+ lymphocyte counts were maintained only among DTH high responders but decreased in the other patients during recurrent viremia (p</=0.02). No other pre-study differences in HIV history or p24-responses were found.

• Authors: Anne-Marte B Kran, Maja A Sommerfelt, Birger Sørensen, Jørgen Nyhus, Ingebjørg Baksaas, Johan N Bruun, Dag Kvale
• Journal: Vaccine (Vaccine) Vol. 23 Issue 31 Pg. 4011-5 (Jul 01 2005) ISSN: 0264-410X [Print] Netherlands
• PMID: 15963359 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• AIDS Vaccines
• HIV Core Protein p24
• RNA, Viral
• Vacc-4x

Topics

• AIDS Vaccines (administration & dosage, immunology)
• Antiretroviral Therapy, Highly Active
• CD4 Lymphocyte Count
• HIV Core Protein p24 (immunology)
• HIV Infections (drug therapy, immunology)
• HIV-1 (immunology)
• Humans
• Hypersensitivity, Delayed
• RNA, Viral (blood)
• Viral Load